-- Recognition Substantiates Marketability of Propess(R) --
PLYMOUTH MEETING, PA., Feb. 27 (Xinhua-PRNewswire) -- BMP Sunstone Corporation (Nasdaq: BJGP) (''BMP Sunstone'' or the ''Company''), today announced that Propess(R) was recommended by the Obstetrics Group at the Obstetrics and Gynecology Branch of the Chinese Medical Association as the first line treatment for labor induction in late-stage pregnancy.
The Guidelines for Labor Induction in Late-Stage Pregnancy was published in the Chinese Journal of Obstetrics and Gynecology in January 2008. The Guidelines recommended Propess(R) as the first choice for cervical ripening, and further provided details on treatment dosage and agent-delivery.
David Gao, Chief Executive Officer of BMP Sunstone, stated, ''The recommendation of Propess(R) by the Chinese Medical Association further validates our research that Propess(R) is a leading product which should be effectively marketed to China's healthcare community. With over 421 Chinese hospitals now selling Propess(R), we have received positive feedback from doctors and will continue to educate healthcare providers about this product. Today's announcement certainly helps our cause."
BMP Sunstone started sales and marketing efforts of Propess(R) in China in 2005, after licensing the drug from its manufacturer, Cytokine PharmaSciences, Inc. (''Cytokine''). Known as Cervidil(R) in the US, Canada, Australia and New Zealand, Propess(R) is a sustained-release formulation of dinoprostone, a synthetic prostaglandin E2 used for cervical ripening in labor induction. Propess(R) is approved for use in over 50 countries around the world.
Denny Willson, President and CEO of Cytokine, stated, ''The Chinese Medical Association's recommendation that Propess(R) be the go-to product for cervical ripening strengthens our ability to educate and ultimately provide care in China. We are so pleased to work with BMP Sunstone to offer this leading product in China and we believe the demand for Propess(R) will continue to increase.''
About Cytokine PharmaSciences, Inc.
Cytokine PharmaSciences is a biopharmaceutical company located in King of Prussia (near Philadelphia), Pennsylvania. The company developed and manufactures Cervidil(R)/Propess(R), used in the obstetrics field for cervical ripening in the induction of labor. Cytokine PharmaSciences is focused on the use of polymers for the delivery of drugs to the vagina or buccal cavity, as well as the development of novel targets and therapeutic agents for the treatment of inflammation, autoimmune diseases and cancer. For more information, visit to http://www.cytokinepharmasciences.com .
About BMP Sunstone Corporation
BMP Sunstone Corporation, through its subsidiaries, is a pharmaceutical marketing and distribution company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China and is pursuing partnerships with other companies seeking to enter the Chinese pharmaceutical market. It is the only U.S. public company to offer industry partners a comprehensive suite of market-entry services in China that includes pre-market entry analysis, clinical trial management, product registration, market research, as well as pharmaceutical marketing and distribution. The Company provides distribution services for a wide range of products, including Western medicines, traditional Chinese medicines, bio-chemical medicines, medical applications, branded generic pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies and equipments. BMP Sunstone's proprietary portfolio primarily focuses on the therapeutic areas of women's health and pediatrics. The Company is headquartered in Plymouth Meeting, Pennsylvania.
Safe Harbor Statement
This news release contains forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements concerning plans, objectives, goals,
strategies, future events or performance, and underlying assumptions and
other statements that are other than statements of historical facts,
including educating healthcare providers and the future demand for
Propess(R). These statements are subject to uncertainties and risks
including, but not limited to, the ability to meet with healthcare
providers and impact the acceptance of the product in the marketplace and
other risks contained in reports filed by the Company with the Securities
and Exchange Commission. All such forward-looking statements, whether
written or oral, and whether made by or on behalf of the company, are
expressly qualified by the cautionary statements and any other cautionary
statements which may accompany the forward-looking statements. In addition,
the Company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date hereof.
For more information, please contact:
BMP Sunstone Corporation:
Fred M. Powell
Chief Financial Officer
Integrated Corporate Relations, Inc.
In the U.S.:
Ashley Ammon MacFarlane and Christine Duan
|SOURCE BMP Sunstone Corporation|
Copyright©2008 PR Newswire.
All rights reserved